
|Videos|February 28, 2018
Dr. Richter on Toxicities of Treatments for Multiple Myeloma
Author(s)Joshua Richter, MD
Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses toxicities in the treatment of patients with multiple myeloma.
Advertisement
According to Richter, toxicities are becoming more of an issue in multiple myeloma. Physicians need to understand where the difficulty comes from. There are many new drugs, and these drugs may offer many patients tremendous outcomes; however, there is also a significant amount of financial burden for the patient and their family.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5






































